released new Guidelines prevention diagnosis treatment chronic hepatitis B HBV infection 2024 Asian Pacific Conference Study Liver Disease APASL Kyoto Japan guideline provide substantial simplification expansion eligibility treatment overcome barrier access HBV testing treatment 250 million people live chronic hepatitis B infection leading increasing death year global burden chronic hepatitis B CHB due mother-to-child transmission shortly birth ’ Global health sector strategy set action target eliminate viral hepatitis 2030 driving new infection death half million globally – reduction 90 65 respectively Considerable progress made towards eliminating mother-to-child transmission HBV universal infant HBV immunization including timely hepatitis B birth dose However hepatitis B birth-dose coverage 45 globally le 20 coverage African Region.For people CHB infection antiviral treatment highly effective improve survival reduce progression liver disease development liver cancer However major testing treatment gap remain 2024 guideline prioritize simplified treatment criterion adult adolescent expanded eligibility antiviral prophylaxis pregnant woman prevent mother-to-child transmission HBV guideline also focus enhancing HBV diagnostics point-of-care viral load testing addressing diagnosis Delta coinfection – major cause HBV-related morbidity mortality – using testing protocol approach delivering high-quality HBV services.OverviewHBV infection major public health problem cause chronic liver disease new guideline provide updated evidence-based recommendation priority HBV-related topic 2015 Guidelines care treatment person diagnosed chronic hepatitis B infection 2017 Guidelines hepatitis B C testing priority area expanded treatment eligibility inclusion adolescent alternative antiviral therapy regimen expanded eligibility antiviral prophylaxis among pregnant woman prevent mother-to-child transmission HBV diagnostics – use point-of-care POC DNA assay reflex HBV DNA testing testing hepatitis delta coinfection andapproaches promote delivery high-quality HBV service including strategy promote adherence long-term antiviral therapy retention care.These guideline also update existing chapter without new recommendation treatment monitoring surveillance liver cancer